Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaume Capdevila

Showing results (91-100 of 192) with videos related to

Pageof 20
Sort By:
Neuroendocrinology|October 4, 2018
Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine NeoplasmsRobert T Jensen, Lisa Bodei, Jaume Capdevila, et al.
Endocrinologia Y Nutricion : Organo De La Sociedad Espanola De Endocrinologia Y Nutricion|November 26, 2015
Spanish consensus for the management of patients with advanced radioactive iodine refractory differentiated thyroid cancerGarcilaso Riesco-Eizaguirre, Juan Carlos Galofré, Enrique Grande, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2023
A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal CancerPaul B Romesser, Jaume Capdevila, Rocio Garcia-Carbonero, et al.
International Journal of Cancer|June 15, 2019
Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patientsFrancesco Sclafani, Sanna Hulkki Wilson, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)Alice Dewdney, David Cunningham, Josep Tabernero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic diseaseFrancesco Sclafani, David Gonzalez de Castro, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2016
Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 StudyJames C Yao, Marianne Pavel, Catherine Lombard-Bohas, et al.
The New England Journal of Medicine|July 12, 2014
Lanreotide in metastatic enteropancreatic neuroendocrine tumorsMartyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, et al.
Endocrine-Related Cancer|January 23, 2019
Genomic profiling of NETs: a comprehensive analysis of the RADIANT trialsJames Yao, Abhishek Garg, David Chen, et al.
Endocrinologia Y Nutricion : Organo De La Sociedad Espanola De Endocrinologia Y Nutricion|January 14, 2015
Spanish consensus for the management of patients with anaplastic cell thyroid carcinomaJosé Manuel Gómez Sáez, Paula Jiménez-Fonseca, Javier Santamaría Sandi, et al.
Pageof 20

Showing results (91-100 of 192) with videos related to

Sort By:
Pageof 20
Neuroendocrinology|October 4, 2018
Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine NeoplasmsRobert T Jensen, Lisa Bodei, Jaume Capdevila, et al.
Endocrinologia Y Nutricion : Organo De La Sociedad Espanola De Endocrinologia Y Nutricion|November 26, 2015
Spanish consensus for the management of patients with advanced radioactive iodine refractory differentiated thyroid cancerGarcilaso Riesco-Eizaguirre, Juan Carlos Galofré, Enrique Grande, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2023
A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal CancerPaul B Romesser, Jaume Capdevila, Rocio Garcia-Carbonero, et al.
International Journal of Cancer|June 15, 2019
Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patientsFrancesco Sclafani, Sanna Hulkki Wilson, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)Alice Dewdney, David Cunningham, Josep Tabernero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic diseaseFrancesco Sclafani, David Gonzalez de Castro, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2016
Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 StudyJames C Yao, Marianne Pavel, Catherine Lombard-Bohas, et al.
The New England Journal of Medicine|July 12, 2014
Lanreotide in metastatic enteropancreatic neuroendocrine tumorsMartyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, et al.
Endocrine-Related Cancer|January 23, 2019
Genomic profiling of NETs: a comprehensive analysis of the RADIANT trialsJames Yao, Abhishek Garg, David Chen, et al.
Endocrinologia Y Nutricion : Organo De La Sociedad Espanola De Endocrinologia Y Nutricion|January 14, 2015
Spanish consensus for the management of patients with anaplastic cell thyroid carcinomaJosé Manuel Gómez Sáez, Paula Jiménez-Fonseca, Javier Santamaría Sandi, et al.
Pageof 20